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Background: Alternate day fasting (ADF; ad libitum “feed day”, alternated with 25% energy intake “fast day”), is
effective for weight loss and cardio-protection in obese individuals. Whether these effects occur in normal weight
and overweight individuals remains unknown. This study examined the effect of ADF on body weight and coronary
heart disease risk in non-obese subjects.
Methods: Thirty-two subjects (BMI 20–29.9 kg/m2) were randomized to either an ADF group or a control group for
12 weeks.
Results: Body weight decreased (P < 0.001) by 5.2 ± 0.9 kg (6.5 ± 1.0%) in the ADF group, relative to the control
group, by week 12. Fat mass was reduced (P < 0.001) by 3.6 ± 0.7 kg, and fat free mass did not change, versus controls.
Triacylglycerol concentrations decreased (20 ± 8%, P < 0.05) and LDL particle size increased (4 ± 1 Å, P < 0.01) in the
ADF group relative to controls. CRP decreased (13 ± 17%, P < 0.05) in the ADF group relative to controls at week 12.
Plasma adiponectin increased (6 ± 10%, P < 0.01) while leptin decreased (40 ± 7%, P < 0.05) in the ADF group versus
controls by the end of the study. LDL cholesterol, HDL cholesterol, homocysteine and resistin concentrations remained
unchanged after 12 weeks of treatment.
Conclusion: These findings suggest that ADF is effective for weight loss and cardio-protection in normal weight
and overweight adults, though further research implementing larger sample sizes is required before solid conclusion
can be reached.
Keywords: Alternate day fasting, Calorie restriction, Weight loss, Cholesterol, Blood pressure, Adipokines, Coronary heart
disease, Non-obese humansIntroduction
Intermittent fasting regimens, particularly alternate
day fasting (ADF) protocols, have gained considerable
popularity in the past decade. Alternate day fasting
involves a “fast day” where individuals consume 25%
of energy needs, alternated with a “feed day” where
subjects eat ad libitum [1]. Only a handful of studies
have been performed to test the effects of ADF on
body weight and coronary heart disease (CHD) risk
reduction, and almost all of these studies have been
undertaken in obese populations (BMI 30–39.9 kg/m2)
[2-4]. Results from these initial trials indicate that* Correspondence: varady@uic.edu
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reproduction in any medium, provided the orADF is effective for weight loss (5-6% reductions in
body weight) and visceral fat mass loss (5–7 cm reductions
in waist circumference) in 8–12 weeks of treatment [2-4].
These reports also suggest that ADF may aid in the
retention of lean mass in obese individuals [2-4]. In
addition to these favorable body composition changes,
improvements in CHD risk have also been noted. For
instance, decreases in LDL cholesterol concentrations
(20-25%), triacylglycerol concentrations (15-30%), and
increases in LDL particle size are often observed with
short-term ADF (8–12 weeks) [2-4]. Beneficial changes
in blood pressure and adipokine profile (i.e. increases
in adiponectin, and decreases in leptin and resistin) have
also been reported [2-4]. Taken together, this preliminaryLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study flow chart. ADF: Alternate day fasting.
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loss and CHD risk reduction in obese adults.
An important question that remains unresolved is
whether the favorable effects of ADF can also be observed
in normal weight and overweight populations. Only two
human studies [5,6] have tested the effect of ADF on
body weight and CHD risk in non-obese subjects. In a
study by Heilbronn et al. [5], normal weight men and
women (BMI 23 kg/m2) participated in an ADF regimen
for 3 weeks. Body weight decreased by 2% from baseline,
while triacylglycerol concentrations decreased only in
men [5]. Contrary to these findings, Halberg et al. [6]
demonstrated no change in body weight after 2 weeks
of ADF in overweight men (BMI 26 kg/m2). While
these trials [5,6] lay some groundwork, they are limited
by their short durations (2–3 weeks) and their lack of a
control group. As such, a longer-term trial (12 weeks)
that employs a control group is well warranted.
Accordingly, the present study examined the effect of
ADF on body weight, body composition, and CHD risk
parameters in both normal weight and overweight adults
in a 12-week randomized controlled feeding trial. We
hypothesized that ADF would reduce body weight and
CHD risk in normal weight and overweight participants,
when compared to controls.
Subjects and methods
Subjects
Subjects were recruited from the Chicago area by means
of advertisements placed around the University of Illinois,
Chicago campus. A total of 107 individuals expressed
interest in the study, but only 32 were recruited to partici-
pate after screening via a preliminary questionnaire and
BMI assessment (Figure 1). Inclusion criteria were as
follows: BMI between 20 and 29.9 kg/m2; age between
35 and 65 years; pre-menopausal or post-menopausal
(absence of menses for more than 2 years); lightly active
(< 3 h/week of light intensity exercise at 2.5 to 4.0
metabolic equivalents (METs) for 3 months prior to the
study); weight stable for 3 months prior to the beginning
of the study (< 4 kg weight loss or weight gain); non-
diabetic; no history of cardiovascular disease; non-smoker;
and not taking weight loss, lipid- or glucose-lowering
medications. The experimental protocol was approved
by the University of Illinois, Chicago, Office for the
Protection of Research Subjects, and all research partici-
pants gave their written informed consent to participate
in the trial. The research protocol was in compliance
with the Helsinki Declaration.
Study design
Experimental design
A 12-week, randomized, controlled, parallel-arm feeding
trial was implemented as a means of testing the studyobjectives. Subjects were randomized by KAV by way of
a stratified random sample. Subjects were first divided
into strata based on sex (M/F), age (35–50 y/51-65 y),
and BMI (20–24.9 kg/m2/ 25–29.9 kg/m2), and then
subjects from each stratum were randomized 1:1 into
either the ADF or control group (Figure 1).
Diet protocol
During the dietary intervention period, ADF subjects
consumed 25% of their baseline energy needs on the fast
day (24 h), and then ate ad libitum on each alternating
feed day (24 h). Energy needs for each subject were
determined by the Mifflin equation [7]. The feed and
fast days began at midnight each day, and all fast day
meals were consumed between 12.00 pm and 2.00 pm
to ensure that each subject was undergoing the same
duration of fasting. ADF subjects were provided with
meals on each fast day (ranging from 400–600 kcal),
and ate ad libitum at home on the feed day. All ADF
fast day meals were prepared in the metabolic kitchen
of the Human Nutrition Research Center (HNRU) at
the University of Illinois, Chicago. Fast day meals were
provided as a 3-day rotating menu, and were formulated
based on the American Heart Association (AHA) guide-
lines (30% kcal from fat, 15% kcal from protein, 55% kcal
from carbohydrate) [8]. All meals were consumed outside
of the research center. ADF subjects were permitted to
consume energy-free beverages, tea, coffee, and sugar-
free gum, and were encouraged to drink plenty of
water. Control subjects were permitted to eat ad libitum
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research center.
Blood collection protocol
Twelve-hour fasting blood samples were collected
between 6.00 am and 9.00 am at baseline (week 1) and
post-treatment (week 12). Participants were instructed
to avoid exercise, alcohol, and coffee for 24 h before
each visit. Blood was centrifuged for 15 min at 520 × g
and 4°C to separate plasma from RBCs, and was stored
at −80°C until analysed.
Analyses
Energy intake on feed and fast days
During the 12-week diet intervention, subjects in the ADF
group were instructed to eat only the foods provided
on each fast day. To assess energy intake on the fast
days, ADF subjects were asked to report any extra food
items consumed (i.e. those not provided) using an
“Extra food log”. Additionally, subjects were instructed
to return any leftover food items to the HNRU for
weighing. To assess energy intake on the feed days,
ADF and control subjects were asked to complete a
3-day food record on 2 feed days during the week, and
on 1 feed day during the weekend, at week 1 and 12.
At baseline, the Research Dietician provided 15 min of
instruction to all participants on how to complete
the food records. These instructions included verbal
information and detailed reference guides on how
to estimate portion sizes and record food items in
sufficient detail to obtain an accurate estimate of
dietary intake. All dietary information from the food
logs/records was entered into the food analysis program,
Nutritionist Pro (version 5, Axxya Systems, Stafford,
TX) to assess energy intake.
Hunger, satisfaction, and fullness
A validated visual analog scale (VAS) was used to measure
hunger, fullness, and satisfaction with the ADF diet [9].
The scale was completed on 3 fast days (before bedtime)
at week 1 and 12. In brief, the VAS consisted of 100-mm
lines, and subjects were asked to make a vertical mark
across the line corresponding to their feelings from 0
(not at all) to 100 (extremely) for hunger, satisfaction,
or fullness. Quantification was performed by measuring the
distance from the left end of the line to the vertical mark.
Weight loss and body composition
Body weight was assessed to the nearest 0.25 kg at the
beginning of every week without shoes and in light
clothing using a balance beam scale at the HNRU
(HealthOMeter, Sunbeam Products, Boca Raton, FL).
BMI was assessed as kg/m2. Body composition (fat
mass and fat free mass) was measured using dual x-rayabsorptiometry (DXA) (Hologic QDR 4500 W, Hologic
Inc., Waltham, MA).
Lipid coronary heart disease risk factors
Plasma total cholesterol, HDL-cholesterol, and triacyl-
glycerol concentrations were measured in duplicate using
enzymatic kits (Biovision Inc., Moutainview, CA) at week
1 and 12. The concentration of LDL-cholesterol was
calculated using the Friedewald, Levy and Fredrickson
equation. LDL particle size was measured by linear poly-
acrylamide gel electrophoresis (Quantimetrix Lipoprint
System, Redondo Beach, CA, USA) at week 1 and 12
[10,11]. High-resolution 3% polyacrylamide gel tubes
were used for electrophoresis. Briefly, 25 μL of sample
was mixed with 200 μL of liquid loading gel containing
Sudan black, and added to the gel tubes. After photo-
polymerization at room temperature for 30 min, samples
were electrophoresed for 1 h (3 mA/gel tube). Lipoware
computer software (Quantimetrix, Redondo Beach, CA,
USA) was then used to divide LDL into small (<255 Å),
medium (255–260 Å), and large (>260 Å) particles, and
to assess mean LDL particle size [10]. The intra-assay
coefficients of variation (CV) for total cholesterol, HDL
cholesterol, triacylglycerol, and LDL particle size were
3.6%, 4.8%, 2.5%, and 4.1%, respectively.
Non-lipid coronary heart disease risk factors
All measurements were taken at week 1 and 12. Blood
pressure was measured in triplicate with the subject in
a seated position after a 10-min rest. C-reactive protein
(CRP) was measured in duplicate using Immulite 1000
High Sensitivity CRP kits (Diagnostic Products Corpor-
ation, Los Angeles, CA). Plasma homocysteine measure-
ments were carried out in duplicate using HPLC with
fluorometric detection. Adiponectin, leptin and resistin
were measure by ELISA (R&D Systems, Minneapolis,
MN). The intra-assay coefficients of variation (CV) for
CRP, homocysteine, adiponectin, leptin, and resistin
were 5.0%, 4.3%, 3.3%, 3.0%, and 4.7%, respectively.
Statistics
Results are presented as means ± standard error of
the mean (SEM). Tests for normality were included in
the model. No variables were found to be not normal.
Differences between groups at baseline were tested by
independent samples t-test. Within-group changes from
week 1 to 12 were tested by a paired t-test. Between-
group differences were tested by an independent sam-
ples t-test. Sample size was calculated assuming a 10%
change in LDL-cholesterol concentrations in the ADF
group, with a power of 80% and an alpha risk of 5%.
P-values of < 0.05 were considered significant. Data were
analyzed by using SPSS software (version 21.0 for Mac
OS X; SPSS Inc., Chicago, IL).
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Subject baseline characteristics and dropouts
Thirty-two subjects commenced the study, with 30 com-
pleting the entire 12-week trial (Figure 1). After loss due
to dropouts, the remaining subjects in each intervention
group were as follows: ADF (n = 15) and control (n = 15).
Baseline characteristics of the subjects who completed the
trial are presented in Table 1. There were no significant
differences at the beginning of the study between groups
for age, sex, ethnicity, body weight, body composition,
height or BMI.Energy intake, hunger, satisfaction and fullness
Energy intake, hunger, satisfaction, and fullness are reported
in Table 2. At baseline, there were no differences between
the ADF and control groups for feed day energy intake.
From week 1 to 12 of the study, energy intake remained
constant on both feed and fast days in the ADF group.
Adherence to the fast day protocol was high in the
ADF group (98 ± 5%). Hunger levels were moderate as
baseline, and did not change by week 12 in either
group. Satisfaction and fullness increased (P < 0.01)
from baseline to post-treatment in the ADF group, with
no change in the control group.Weight loss and body composition
Changes in body weight and body composition are
displayed in Figure 2. Body weight decreased (P < 0.001)
by 5.2 ± 0.9 kg (6.5 ± 1.0%) in the ADF group, relative
to the control group at week 12. Fat mass was reduced
(P < 0.001) by 3.6 ± 0.7 kg, and fat free mass did not
change, versus controls.Table 1 Subject characteristics at baseline
ADF-ALL Control P-value1
n 15 15
Age (y) 47 ± 3 48 ± 2 0.18
Sex (M/F) 5 / 10 3 / 12 0.44
Ethnicity (n)




Body weight (kg) 77 ± 3 77 ± 3 0.79
Fat mass (kg) 26 ± 2 27 ± 1 0.13
Fat free mass (kg) 51 ± 3 50 ± 3 0.78
Height (cm) 171 ± 3 170 ± 2 0.71
BMI (kg/m2) 26 ± 1 26 ± 1 0.75
Values reported as mean ± SEM. ADF: Alternate day fasting, BMI: Body mass
index, F: Female, M: Male.
1P-value between groups at baseline: Independent samples t-test.Lipid coronary heart disease risk factors
Changes in plasma lipids and LDL particle size are
reported in Table 3. Total cholesterol concentrations
decreased (P < 0.01) in the ADF group when post-
treatment values were compared to baseline. However,
changes in total cholesterol levels were not significantly
different from controls at week 12. LDL cholesterol
concentrations were reduced (P = 0.01) within the ADF
group, but no significant between-group differences
were noted. HDL cholesterol concentrations remained
unchanged throughout the trial. Triacylglycerol concen-
trations decreased (P = 0.01) in the ADF group relative
to controls at week 12. Non-HDL cholesterol levels
were reduced (P < 0.01) within the ADF group, but no
significant between-group differences were observed.
LDL particle size increased (P < 0.01) in the ADF group
relative to controls by the end of the study.
Non-lipid coronary heart disease risk factors
Changes in blood pressure, homocysteine, CRP, and
adipokines are shown in Table 4. Systolic and diastolic
blood pressure decreased (P < 0.05) within the ADF
group, but no significant between-group differences
were noted. CRP decreased (P = 0.01) in the ADF group
relative to controls at week 12. Plasma adiponectin
increased (P < 0.01) while leptin decreased (P = 0.03) in
the ADF group versus controls by the end of the study.
Plasma homocysteine and resistin concentrations
remained unchanged after 12 weeks of treatment.
Discussion
This study shows, for the first time, that ADF is an
effective strategy for moderate weight loss (6%) in nor-
mal weight and overweight subjects. This diet strategy
may also have cardio-protective effects in non-obese
subjects, by way of lowering triacylglycerols, CRP and
leptin, while increasing LDL particle size and adiponectin
concentrations.
The primary goal of this study was to determine if
non-obese individuals could benefit from ADF in terms
of weight loss. Previous ADF studies implementing
non-obese subjects report inconsistent findings [5,6].
While one study demonstrated decreases in body weight
of 2% from baseline after 3 weeks of ADF [5], another
study showed no effect after 2 weeks of diet [6]. The
limited amount of weight loss reported previously is
undoubtedly a factor of the short trial durations imp-
lemented [5,6]. Thus, we wanted to determine if the
degree of weight loss could be amplified if the trial
duration was extended to 12 weeks. We show here that
normal weight and overweight subjects can indeed
benefit from ADF, as body weight was reduced by 6%
(5 kg) by the end of the trial. This degree of weight loss
in non-obese participants is similar to what has been
Table 2 Energy intake, hunger, satisfaction and fullness during the 12-week study
Intervention Week 11 Week 12 P-value2 P-value3 Change4 P-value5
Feed day energy intake (kcal/d) ADF 1874 ± 136 1856 ± 229 0.93 0.92 −18 ± 186 0.50
Control 1873 ± 243 1790 ± 286 0.71 −82 ± 75
Fast day energy intake (kcal/d) ADF 482 ± 19 489 ± 20 0.74 7 ± 5
Hunger (mm) ADF 5 ± 1 4 ± 1 0.44 0.56 −1 ± 1 0.38
Control 5 ± 1 5 ± 1 0.46 0 ± 1
Satisfaction (mm) ADF 4 ± 1 7 ± 1 <0.01 0.81 3 ± 1 0.22
Control 6 ± 1 7 ± 1 0.34 1 ± 1
Fullness (mm) ADF 2 ± 1 4 ± 1 <0.01 0.78 2 ± 1 0.01
Control 6 ± 1 6 ± 1 0.57 0 ± 1
Values reported as mean ± SEM. ADF: Alternate day fasting.
1Baseline values were not significantly different between intervention groups for any parameter: Independent samples t-test.
2P-value between week 1 and week 12: Paired t-test.
3P-value between groups at week 12: Independent samples t-test.
4Absolute change between week 1 and week 12 values.
5P-value between groups for absolute change: Independent samples t-test.
Varady et al. Nutrition Journal 2013, 12:146 Page 5 of 8
http://www.nutritionj.com/content/12/1/146reported for obese individuals undergoing ADF [2-4].
For instance, Bhutani et al. [4] demonstrated 5% (5 kg)
weight loss after 12 weeks of ADF in obese men and
women. In line with these findings, Klempel et al. [3]
and Varady et al. [2] report 5-6% (5–6 kg) weight loss
after 8 weeks of treatment in obese subjects. Thus, ADF
may produce a mean rate of weight loss of approximately
0.5 kg/week, independent of the starting weight or BMI
class of the subject. Fat free mass was also retained
after 12 weeks of ADF in non-obese individuals. This
finding is similar to what has been reported in previous
short-term studies of ADF [2-4]. As such, the beneficial
preservation of fat free mass observed in obese individuals
[2-4] may be replicated in non-obese subjects participating
in ADF protocols.Figure 2 Body weight and body composition changes at week
12. Values reported as mean ± SEM. ADF: Alternate day fasting.
*Body weight and fat mass significantly different (P < 0.001) from the
control group at week 12 (Independent samples t-test). No difference
between groups for fat free mass at week 12 (Independent
samples t-test).Our findings also indicate that normal weight and
overweight subjects have no problem adhering to the
fast day protocol for 12 weeks. Dietary adherence was
very high at baseline (98%), and did not wane over the
course of the study. It should be noted, however, that
one normal weight subject dropped out of the trial due
to an inability to adhere to the diet. Notwithstanding,
our dropout rate was still less than 10%, which is similar
to the dropout rate of studies performed in obese individ-
uals [2-4]. Complementary to previous reports [12,13],
there was very little or no hyperphagic response on the
feed day in response to the lack of food on the fast day.
This lack of hyperphagia allowed for overall energy
restriction to remain high throughout the study, and
undoubtedly contributed to the sizeable degree of weight
loss observed here. As for eating behaviors, perceived
hunger was moderate at baseline and did not change
by week 12. This is contrary to findings in obese par-
ticipants, which consistently show declines in hunger
after 8–12 weeks of ADF [11,12]. Dietary satisfaction
and feelings of fullness, on the other hand, increased
from baseline to post-treatment. These increases in
satisfaction and fullness have also been noted in obese
subjects [11,12], and may play a role in long-term
adherence to the diet.
The cardio-protective effects of ADF were also exam-
ined. Reductions in triacylglycerol concentrations (20%)
were noted after 12 weeks of ADF. LDL particle size
also increased post-treatment (4 Å from baseline).
These changes in lipid risk factors are in line with what
has been reported for obese ADF subjects [14,15]. In
two recent ADF studies, triacylglycerols decreased by
15% and LDL particle size increased by 2–3 Å after
8 weeks of treatment in obese men and women [14,15].
Thus, ADF may improve plasma lipids to the same
extent in non-obese subjects as it does in obese
Table 3 Lipid coronary heart disease risk factor changes during the 12-week study
Intervention Week 11 Week 12 P-value2 P-value3 Change4 P-value5
Total cholesterol (mg/dl) ADF 201 ± 9 175 ± 12 <0.01 0.12 −26 ± 6 0.50
Control 211 ± 11 202 ± 9 0.54 −9 ± 5
LDL cholesterol (mg/dl) ADF 118 ± 9 99 ± 9 0.01 0.82 −18 ± 6 0.29
Control 128 ± 10 119 ± 6 0.08 −9 ± 4
HDL cholesterol (mg/dl) ADF 56 ± 3 54 ± 4 0.49 0.77 −2 ± 3 0.51
Control 57 ± 2 58 ± 4 0.83 1 ± 2
Triacylglycols (mg/dl) ADF 109 ± 13 87 ± 9 0.06 0.01 −22 ± 11 0.22
Control 108 ± 18 118 ± 19 0.34 10 ± 7
Non-HDL cholesterol (mg/dl) ADF 149 ± 11 124 ± 12 <0.01 0.54 −25 ± 5 0.96
Control 153 ± 12 144 ± 10 0.79 −9 ± 5
LDL particle size (Å) ADF 254 ± 1 258 ± 2 <0.01 <0.01 4 ± 1 0.13
Control 252 ± 2 250 ± 3 0.16 −2 ± 1
Values reported as mean ± SEM. ADF: Alternate day fasting.
1Baseline values were not significantly different between intervention groups for any parameter: Independent samples t-test.
2P-value between week 1 and week 12: Paired t-test.
3P-value between groups at week 12: Independent samples t-test.
4Absolute change between week 1 and week 12 values.
5P-value between groups for absolute change: Independent samples t-test.
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in circulating leptin and CRP concentrations, in con-
junction with increases in adiponectin, were also noted
in non-obese subjects undergoing ADF. As for HDL
cholesterol, homocysteine, and resistin concentrations,
no effect was observed. This lack of effect is not surprising
as these CHD risk parameters are generally only improved
with >10% weight loss [16-18].Table 4 Non-lipid coronary heart disease risk factor changes
Intervention Week 11 We
Systolic BP (mm Hg) ADF 124 ± 4 11
Control 119 ± 3 12
Diastolic BP (mm Hg) ADF 78 ± 3 7
Control 82 ± 4 8
Homocysteine (umol/dl) ADF 9 ± 1 9
Control 9 ± 1 9
C-reactive protein (mg/L) ADF 2 ± 1 1
Control 1 ± 1 1
Adiponectin (ng/ml) ADF 10728 ± 1251 1140
Control 11350 ± 1369 1050
Leptin (ng/ml) ADF 25 ± 4 1
Control 22 ± 7 1
Resistin (ng/ml) ADF 18 ± 3 1
Control 23 ± 4 2
Values reported as mean ± SEM. ADF: Alternate day fasting.
1Baseline values were not significantly different between intervention groups for an
2P-value between week 1 and week 12: Paired t-test.
3P-value between groups at week 12: Independent samples t-test.
4Absolute change between week 1 and week 12 values.
5P-value between groups for absolute change: Independent samples t-test.It will be of interest in future studies to determine
how alterations in macronutrient intake on the fast day
may affect weight loss and cardiovascular outcomes. For
instance, it has been well established that Mediterranean
[19] and certain low-carbohydrate diets [20] help to
maintain a healthy body weight and reduce CHD
risk. Whether further reductions in body weight and
CHD risk would occur if ADF were combined withduring the 12-week study
ek 12 P-value2 P-value3 Change4 P-value5
7 ± 4 0.02 0.85 −7 ± 2 0.51
0 ± 4 0.67 1 ± 3
2 ± 2 0.03 0.05 −6 ± 2 0.17
4 ± 5 0.28 2 ± 6
± 1 0.37 0.50 0 ± 1 0.21
± 1 0.86 0 ± 1
± 1 0.29 0.01 −1 ± 1 0.01
± 1 0.78 0 ± 1
1 ± 1197 0.58 0.15 672 ± 1191 <0.01
9 ± 1316 0.26 −842 ± 623
5 ± 3 0.04 0.55 −10 ± 3 0.03
8 ± 6 0.07 −4 ± 3
5 ± 4 0.15 0.57 −3 ± 3 0.20
1 ± 4 0.26 −2 ± 2
y parameter: Independent samples t-test.
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warrants investigation.
A couple of adverse events were reported during the
study. Two subjects experienced mild headaches during
week 1 of the trial, which may or may not be related to
dietary treatment. One other subject reported constipa-
tion during week 1 and 2 of the trial. The subject was
advised to consume more fruits and vegetables on feed
days, and the constipation subsided by week 3 of the
dietary intervention period.
This study has several limitations. First and foremost,
it must be acknowledged that this pilot study was origin-
ally designed to compare the effects of ADF in normal
weight versus overweight individuals on body weight
and CHD risk. Due to a low recruitment rate, we were
only able to recruit n = 8 subjects into the normal weight
group and n = 8 subjects into the overweight group. In
view of this, we decided to combine the normal weight
and overweight groups into one group to increase
sample size. This post hoc change should be taken
into consideration when interpreting the findings of
this paper. Secondly, physical activity was not assessed
throughout the trial, thus the degree of weight loss
associated with increased energy expenditure from
exercise is not known. Thirdly, the sample size of each
group was small (n = 15). Thus, this study may not be
adequately powered to detect changes in certain CHD risk
parameters (e.g. resistin). Fourthly, this study employed
food records to assess dietary intake/adherence. It is
well known that overweight subject underreport food
intake by ~30% [21,22]. Thus, our findings for the hy-
perphagic response on the feed day may be inaccurate.
In summary, these preliminary findings suggest that
ADF is a viable weight loss strategy for normal weight
and overweight individuals wishing to lose a moderate
amount of weight (5–6 kg) within a relatively short
period of time (12 weeks). This diet may also help lower
CHD risk in non-obese individuals, though further
investigation is warranted to confirm these effects. It
should also be noted that the purpose of this paper is to
report pilot feasibility findings. It is our hope that this
preliminary data will be utilized to design larger-scale
longer-term trials with similar objectives, in normal
weight and overweight participants undergoing ADF.Competing interest
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